FDA issues Complete Response Letter for RLX030 for acute heart failure MarketWatch (Thomson Reuters ONE via COMTEX) -- Novartis International AG / FDA issues Complete Response Letter for RLX030 for acute heart failure . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of ... Novartis Says FDA Issues CRL For RLX030 For Acute Heart Failure - Quick Facts Novartis to Provide More Evidence for Heart Drug Serelaxin Novartis Fails to Win U.S. Approval for Serelaxin Heart Drug |
